JPRN-jRCT2080220345未知3 期
Correction study of intravenous injections of R744 to Hemodialysis patients ( Phase III study ).
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Adult patients >=20 years of age
- •Hemodialysis patients
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Correction Study of R744 in Renal Anemia Patients on HemodialysisHemodialysis PatientsNCT00433693Chugai Pharmaceutical50
未知
2 期
A study of intravenous R744 in renal anemia patients on hemodialysis.AnemiaJPRN-jRCT2080220218Chugai Pharmaceutical Co., Ltd.
未知
2 期
A study of intravenous R744 in chronic renal failure patients with renal anemia.AnemiaJPRN-jRCT2080220220Chugai Pharmaceutical Co., Ltd.
未知
2 期
A study of switching from rHuEPO to intravenous R744 in renal anemia patients on hemodialysis.AnemiaJPRN-jRCT2080220219Chugai Pharmaceutical Co., Ltd.
未知
3 期
HERA study: A study of Intravenous R597 (Trastuzumab) in Women with HER2-Positive Primary Breast CancerBreast CancerJPRN-jRCT2080220185Chugai Pharmaceutical Co., Ltd.